"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
A trial comparing trametinib with chemotherapy for melanoma that has spread
This trial looked at a new drug called trametinib (GSK1120212) for advanced melanoma. It was for people with a change in a gene called BRAF in their melanoma cells.
The BRAF gene affects how cells divide and grow (cell division). In some people the gene is changed or damaged. This is called a gene
If the BRAF gene is faulty, it affects a protein called mitogen activated protein kinase (MEK). MEK is involved in cell division, and can make cancer cells keep dividing out of control.
In this trial, researchers looked at a drug called trametinib which blocks MEK and can stop melanoma cells growing. It is called a MEK inhibitor.
This trial was for people who had melanoma that had spread to lymph nodes (stage 3C) or to another part of the body (stage 4). This is called advanced melanoma. Doctors can use chemotherapy to treat advanced melanoma, but they are looking for ways to improve treatment.
The aims of the trial were to see
- If trametinib was better than chemotherapy for people with advanced melanoma
- How trametinib affected
quality of life
Summary of results
The trial team found that trametinib was better than chemotherapy for advanced melanoma with a change in the BRAF gene.
- 214 people had trametinib
- 108 people had chemotherapy
The trial team looked at the average length of time it took for melanoma to come back. For those who had trametinib it was just under 5 months. For those who had chemotherapy it was 1½ months.
After treatment the team looked at how many people had no sign of cancer (a
- 22 out of every 100 people (22%) who had trametinib had cancer that had disappeared or shrunk
- 8 out of every 100 people (8%) who had chemotherapy had cancer that had disappeared or shrunk
At 6 months after treatment, the team looked at how many people were alive. They found that
- 81 out of every 100 people (81%) who had trametinib were alive
- 67 out of every 100 people (67%) who had chemotherapy were alive
The most common side effects of trametinib were
The most common side effects of chemotherapy were
The trial team concluded that trametinib was better than chemotherapy for treating advanced melanoma. And that further studies should be done to find the best role for trametinib in treating advanced melanoma.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Paul Nathan
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer